These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20510009)

  • 1. [Protective effect of silibinin on liver injury induced by antituberculosis drugs].
    Li J; Lin WF; Pan YY; Zhu XY
    Zhonghua Gan Zang Bing Za Zhi; 2010 May; 18(5):385-6. PubMed ID: 20510009
    [No Abstract]   [Full Text] [Related]  

  • 2. [Functional state of the liver in patients with pulmonary tuberculosis against a background of antibacterial therapy].
    Latyshev NN
    Probl Tuberk; 1967; 45(9):54-8. PubMed ID: 5606480
    [No Abstract]   [Full Text] [Related]  

  • 3. [Functional state of the liver in patients with pulmonary tuberculosis during treatment with chemopreparations of the 2d series].
    Vasilik GV
    Probl Tuberk; 1968; 46(8):43-7. PubMed ID: 5709113
    [No Abstract]   [Full Text] [Related]  

  • 4. [Several indices of the antitoxic function of the liver in pulmonary tuberculosis and their changes under the influence of hepatotropic therapy].
    Fitsaĭ AV
    Ter Arkh; 1971 Oct; 43(10):47-50. PubMed ID: 5140952
    [No Abstract]   [Full Text] [Related]  

  • 5. [State of the liver in middle-aged and elderly patients with pulmonary tuberculosis under prolonged chemotherapy].
    Iashchenko BP; Iakimets VP
    Vrach Delo; 1971 Oct; 10():86-90. PubMed ID: 5142544
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatic dysfunction during antituberculosis treatment of HB antigens carriers].
    Pawlak F
    Pneumonol Pol; 1977 Sep; 45(9):605-8. PubMed ID: 928155
    [No Abstract]   [Full Text] [Related]  

  • 8. [Certain indicators of liver function in patients with disseminated destructive pulmonary tuberculosis after intravenous administration of drugs].
    Ganushchak MM; Dubosarskiĭ AI
    Probl Tuberk; 1973; 51(3):45-7. PubMed ID: 4771054
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative study of the concordance of results of determination of the activity of ornithine carbamoyltransferase, alanine transaminase and bilirubin in blood serum and the assessment of hepatic function in patients with pulmonary tuberculosis treated with drugs with special reference to hepatotoxic drugs].
    Pregowski W
    Gruzlica; 1973; 41(5):431-40. PubMed ID: 4710619
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparative evaluation of several functional tests of the liver in patients with pulmonary tuberculosis with side-reactions to tuberculostatic preparations].
    Kaminskaia GO; Karachunskiĭ MA; Kolosovskaia VP
    Ter Arkh; 1969 Nov; 41(11):75-9. PubMed ID: 5384752
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combining antitubercular agents of similar hepatic toxicity].
    Niemirowska H; Pecyna-Sielewicz J; Styszewska H; Wareska W
    Gruzlica; 1975 Jan; 43(1):37-46. PubMed ID: 1110038
    [No Abstract]   [Full Text] [Related]  

  • 12. [Frequency and character of side effects of anti-tubercular drugs].
    Kazakov KS; Kalankhodzhaev AA; Kozarez MI; Atamatov KhA; Mukhtarov DZ; Ikramova MI; Gamzaeva NF; Magrupov IaA
    Probl Tuberk; 1991; (12):28-31. PubMed ID: 1803369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enzymatic parameters of the liver function in patients with active pulmonary tuberculosis and adverse reactions to chemotherapeutic drugs].
    Bondarenko VP
    Probl Tuberk; 1979 Nov; (11):37-40. PubMed ID: 530967
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk factors for drug induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis.
    Pore SM; Shinde K
    J Postgrad Med; 2014; 60(1):90-2. PubMed ID: 24625953
    [No Abstract]   [Full Text] [Related]  

  • 15. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.
    Luangchosiri C; Thakkinstian A; Chitphuk S; Stitchantrakul W; Petraksa S; Sobhonslidsuk A
    BMC Complement Altern Med; 2015 Sep; 15():334. PubMed ID: 26400476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and experimental studies of liver damages in tuberculosis, with special reference to liver damages caused by antitubercular agents and the autonomic nervous factor].
    Homma Y
    Iryo; 1969 Apr; 23(4):482-501. PubMed ID: 5804545
    [No Abstract]   [Full Text] [Related]  

  • 17. [Morphologic and functional picture of the liver in recent pulmonary tuberculosis and its evolution after chemoantibiotic therapy].
    Greco S; Dusi U; Menozzi V
    Riv Anat Patol Oncol; 1964 Jun; 25(6):Suppl:431-52. PubMed ID: 5827720
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of pyrazinamide on the liver of tuberculosis patients. Electron microscopic study].
    Pilheu JA; de Salvo MC; Koch OR; Arias RF
    Bull Int Union Tuberc; 1984 Sep; 59(3):145-7. PubMed ID: 6518323
    [No Abstract]   [Full Text] [Related]  

  • 19. Liver function in active pulmonary tuberculosis during complex therapy including ethambutol.
    Ushakova AG
    Probl Tuberk; 1974; (11):37-40. PubMed ID: 4449840
    [No Abstract]   [Full Text] [Related]  

  • 20. [The impact of antituberculosis drugs upon liver function in patients with positive HBVM].
    Chen GQ
    Zhonghua Jie He He Hu Xi Za Zhi; 1989 Apr; 12(2):89-90, 126. PubMed ID: 2791129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.